-
公开(公告)号:US20220008354A1
公开(公告)日:2022-01-13
申请号:US17289932
申请日:2019-10-31
发明人: Elka TOUITOU , Hiba NATSHEH
IPC分类号: A61K31/05 , A61K9/00 , A61K47/24 , A61K9/48 , A61K31/352
摘要: Essentially water-free liquid composition for oral administration, comprising: from 25% to 75% by weight of one or more cannabinoid (s); and from 25% to 59% by weight one or more phospholipid (s); and optionally one or more antioxidants (s).
-
公开(公告)号:US20220007686A1
公开(公告)日:2022-01-13
申请号:US17289576
申请日:2019-10-31
发明人: Elka TOUITOU , Hiba NATSHEH
摘要: Cannabinoids-containing aqueous beverage comprising cannabinoids and phospholipids.
-
3.
公开(公告)号:US20220370350A1
公开(公告)日:2022-11-24
申请号:US17836617
申请日:2022-06-09
发明人: Elka TOUITOU , Hiba NATSHEH
IPC分类号: A61K9/107 , A61P25/16 , A61K38/095 , A61K9/00 , A61K31/047 , A61K31/05 , A61K31/135 , A61K31/165 , A61K31/192 , A61K31/4196 , A61K31/426 , A61K31/485 , A61K31/551 , A61K38/12 , A61K38/18 , A61K38/28 , A61K47/02 , A61K47/10 , A61K47/24
摘要: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.
-
公开(公告)号:US20210369799A1
公开(公告)日:2021-12-02
申请号:US17290908
申请日:2019-10-31
发明人: Elka TOUITOU , Hiba NATSHEH
摘要: A nasal composition comprising one or more vegetable oils that possess medicinal properties for the treatment or improvement of brain/central nervous system conditions and diseases; phospholipids and optionally glycol, the composition being cannabinoids-free.
-
公开(公告)号:US20200345656A1
公开(公告)日:2020-11-05
申请号:US16767799
申请日:2018-11-04
发明人: Elka TOUITOU , Hiba NATSHEH
摘要: A composition for administration into the nasal cavity, the rectal cavity and the vaginal cavity, wherein the composition is an essentially non-aqueous composition comprising: not less than 25% by weight of one or more cannabinoid(s); from 25% to 55% by weight one or more phospholipid(s); and optionally one or more antioxidant(s).
-
6.
公开(公告)号:US20200268662A1
公开(公告)日:2020-08-27
申请号:US16814163
申请日:2020-03-10
发明人: Elka TOUITOU , Hiba NATSHEH
IPC分类号: A61K9/107 , A61K38/28 , A61K9/00 , A61K47/24 , A61K47/10 , A61K47/02 , A61K38/18 , A61K38/095 , A61K31/135 , A61K31/4196 , A61K31/047 , A61K31/05 , A61K31/551 , A61K31/485 , A61K31/192 , A61K38/12 , A61K31/165 , A61K31/426 , A61P25/16
摘要: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.
-
-
-
-
-